SEC Form 4	
------------	--

 \Box

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol <u>PTC THERAPEUTICS, INC.</u> [PTCT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
<u>Kranda Michael L</u>					<u>I TO THEIMFEOTICS, INC.</u> [FICI]								X Directo	r		10% Ow	ner			
-																(give title		Other (s	pecify	
(Last)	(F	First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year)									below)			below)		
C/O PTC THERAPEUTICS, INC.				01/	01/02/2015															
100 CORPORATE COURT																				
					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ir	6. Individual or Joint/Group Filing (Check Applicable						
(Street)															Line)					
SOUTH			07000												-	filed by One Reporting Person				
PLAINFIELD NJ 07080															Form filed by More than Person			ting		
(City)	(5	State)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of S	Security (Ins	tr. 3)		2. Trans	action		A. Deeme		3.		4. Securi				5. Amoui				. Nature	
Date (Month/D				Execution Date Day/Year) if any			Date	e, Transaction Disposed Code (Instr. 5)			d Of (D) (Instr. 3, 4 a			Securitie Beneficia				of Indirect Beneficial		
												Owned F Reported	olĺowing	(l) (Instr. 4)		Ownership Instr. 4)				
						Code	v	Amount	Amount (A) or (D)		Price	Transact	tion(s)		ľ					
										(D)			(Instr. 3 and 4)							
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of	2.	3. Transaction	3A. Deeme	d 4	I.		5. Numb	per	6. Date E	xerci	sable and	7. Tit	tle and a	Amount	8. Price of	9. Numbe	r of	10.	11. Nature	
Derivative Security	Conversion or Exercise	Date (Month/Day/Year)	Execution if any	Date, T	Transaction Code (Instr.		n of		Expiration (Month/E	on Da	te	of Se	ecurities erlying		Derivative Security	derivative Securities		Ownership Form:	of Indirect Beneficial	
(Instr. 3)	Price of	(Month/Day/Teal)	(Month/Day			nsu.	Securities			ayin	cai j	Deriv	vative S		(Instr. 5)	Beneficially		Direct (D)	Ownership	
	Derivative Security				Acquired (A) or			d	(Instr. 3 and 4)					4)		Owned Following		or Indirect (I) (Instr. 4)	(Instr. 4)	
				Disposed of (D) (Instr.								Reported Transaction(s)								
					3, 4 and 5)									(Instr. 4)	(0)					
											Amount									
														or Number						
					Code V (A) (D)			Date Exercisa	ble	Expiration Date	Title	c	of Shares							

buy) **Explanation of Responses:**

\$<mark>51</mark>

01/02/2015

Stock Option

(right to

/s/ Colleen Diver Johnson, Attorney-in-Fact

01/01/2025

Common

Stock

01/02/2015

12,000

D

** Signature of Reporting Person Date

12,000

\$51

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

(A)

12.000

01/02/2016

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Limited Power Of Attorney For Section 16 Reporting Obligations

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Mark E. Boulding, Colleen Diver Johnson, Donald Mankoff and Martin Rexroad, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of, and/or holder of equity in, PTC Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering Analysis and Retrieval System of the SEC;

(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this June 9, 2014.

Signature /s/ Michael Kranda Name: Michael Kranda